Everolimus

Immunogen Epoxide hydrolase 2 recombinant protein epitope signature tag (PrEST) Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by

The gene LETM2 (leucine zipper and EF-hand containing transmembrane protein 2) is mapped to human chromosome 8. The function of it is currently unknown.

PRR7 (proline rich 7) is a transmembrane adaptor protein, that is located at the plasma membrane and to large vesicular perinuclear structures. It is expressed in several tissues, including leukocytes and is upregulated upon activation of T cell.

AntiHum TLR2,Pure(Clone 11G7,Mse IgG)200ug

HOST SPECIES: Rabbit CLONALITY: Polyclonal TESTED APPLICATIONS: E, WB APPLICATIONS: EVER2 antibody can be used for detection of EVER2 by Western blot at 1 - 2 &#956g/mL. Antibody validated: Western Blot in rat samples.

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

Everolimus (RAD001), a derivative of rapamycin, is commonly used as a drug for the inhibition of the mTOR pathway, affecting tumor cell division and angiogenesis. Application Everolimus may be used as a standard in the following clinical studies:

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.An immunosuppresive inhibitor of FRAP (mTOR).

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.An immunosuppresive inhibitor of FRAP (mTOR).

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.An immunosuppresive inhibitor of FRAP (mTOR).

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.An immunosuppresive inhibitor of FRAP (mTOR).

InformationIn vitroEverolimus exhibits the immunosuppressive activity which is comparable to that of rapamycin. Everolimus competes with immobilized FK 506 for binding to biotinylated FKBP12 and shows the inhibitory effect on a two-way MLR performed